Retatrutide vs Foundayo (Orforglipron): Injectable vs Oral GLP-1

The obesity therapeutics pipeline is expanding rapidly. Global obesity prevalence now exceeds 1 billion adults, and the severe-obesity segment remains underserved — context that helps explain why maximum-efficacy compounds like retatrutide attract as much research attention as convenience-oriented oral agonists like orforglipron.

How Do Retatrutide and Orforglipron Compare?

Retatrutide and orforglipron are both Eli Lilly obesity drugs in Phase 3 development, but they represent fundamentally different therapeutic strategies. Retatrutide (LY-3437943) is a triple agonist that activates three receptors simultaneously — GLP-1, GIP, and glucagon — and is delivered as a once-weekly subcutaneous injection. Orforglipron (LY3502970) is a non-peptide small molecule that targets the GLP-1 receptor only and is taken as a once-daily oral pill.

The two drugs are not designed to compete with each other. Lilly’s pipeline positions retatrutide as the maximum-efficacy option where weight-loss magnitude is the priority, while orforglipron addresses the large share of the market that prefers oral dosing. An oral format may also broaden research-protocol access where injectable delivery isn’t practical, while an injectable offers the broadest metabolic engagement for efficacy-focused studies. This complementary positioning mirrors how Lilly already markets tirzepatide (Mounjaro/Zepbound) alongside its broader pipeline. For the latest on orforglipron’s regulatory timeline, see our orforglipron FDA status tracker and our deep-dive on Foundayo (orforglipron).

What Is the Difference in Mechanism?

Retatrutide is a triple agonist that simultaneously activates three metabolic receptors — GLP-1, GIP, and glucagon — which together regulate appetite, energy expenditure, and hepatic lipid handling. GLP-1 receptor activation suppresses appetite and slows gastric emptying. GIP receptor activation enhances insulin sensitivity and may contribute to fat metabolism. Glucagon receptor activation increases energy expenditure and hepatic lipid oxidation. This three-receptor approach engages metabolic pathways that single-agonist drugs do not reach.

Triple agonists are part of a next-generation design thesis in metabolic research: engaging multiple incretin and non-incretin receptors to reach weight-loss magnitudes that single GLP-1 compounds have not matched in published Phase 2 and Phase 3 data. Glycemic endpoints (including HbA1c changes) have also tracked with mechanism breadth across the class.

Orforglipron is a GLP-1 receptor agonist only. It activates the same GLP-1 receptor as semaglutide and liraglutide, suppressing appetite and slowing gastric emptying. The key innovation is structural: orforglipron is a non-peptide small molecule, which allows oral delivery without the fasting requirements that constrain peptide-based oral GLP-1 drugs like the Wegovy pill. We compare it to other oral formulations in our oral obesity drugs 2026 analysis.

In short, retatrutide’s advantage is mechanistic breadth — three receptors instead of one. Orforglipron’s advantage is structural — a small molecule format that enables convenient oral dosing. For a deeper look at how the GLP-1, GIP, and glucagon pathways interact, see our triple agonist pathway explainer.

How Does the Weight Loss Data Compare?

The primary endpoint in both programs was percentage change in body weight from baseline. Retatrutide’s Phase 3 figure is the strongest reported in any late-stage obesity trial to date; orforglipron’s 12.4% sits inside the 9–15% band typical of injectable GLP-1 agonists such as semaglutide — see our GLP-1 class comparison for how those numbers stack up.

Retatrutide reported 28.3% mean weight loss at 80 weeks on the 12 mg dose in the pivotal TRIUMPH-1 obesity trial (topline May 21, 2026), rising to 30.3% at 104 weeks in the BMI ≥35 extension. The Phase 3 dose curve was 4 mg 19.0%, 9 mg 25.9%, 12 mg 28.3%, with 45.3% of 12 mg participants achieving ≥30% weight loss. TRIUMPH-4 separately reported 28.7% at 68 weeks (obesity with knee osteoarthritis, December 2025). In the earlier Phase 2 trial, the 12 mg dose achieved 24.2% weight loss at 48 weeks, published in the New England Journal of Medicine in 2023.

Foundayo (orforglipron) reported 12.4% mean weight loss at 72 weeks in the ATTAIN-1 Phase 3 trial at the FDA-approved 17.2 mg dose. The Phase 2 trial showed up to 14.7% weight loss at 36 weeks. The ATTAIN-MAINTAIN readout (May 12, 2026) added a maintenance-dosing use case: Foundayo plus lower-dose Zepbound held weight after participants switched from max-tolerated Wegovy, with modest regain (~0.9–5 kg by cohort). A separate ATTAIN post-hoc analysis (May 2026) showed comparable weight loss in older adults aged 65 and over.

Important caveat: These figures come from different clinical trials with different patient populations, baseline weights, dose titration schedules, and trial durations. Cross-trial comparisons are informative but not definitive. Only a head-to-head trial could establish true relative efficacy, and no such trial has been announced. For broader context on how both drugs compare to tirzepatide and CagriSema, see our three-way obesity drug comparison.

What Are the Side Effects of Each?

Both retatrutide and orforglipron produce gastrointestinal side effects that are characteristic of incretin-class drugs. The most common events in both programs are nausea, diarrhea, and vomiting. These are generally described as mild to moderate in severity and tend to decrease over time with continued dosing.

Retatrutide reported nausea in approximately 25–30% of participants in clinical trials, with diarrhea and vomiting also occurring. The TRIUMPH-1 Phase 3 readout (May 21, 2026) added a clean dose-dependent discontinuation-due-to-AE curve of 4.1% / 6.9% / 11.3% across 4 / 9 / 12 mg vs 4.9% placebo, plus new Phase 3 signals of dysesthesia up to 12.5% on 12 mg and UTIs — safety detail that will be presented in full at the ADA Scientific Sessions in June 2026. The triple-agonist mechanism — particularly the glucagon receptor component — raises theoretical questions about hepatic effects, though Phase 3 data has not flagged liver-related signals as a primary concern.

Orforglipron reported nausea in approximately 30% of participants, with vomiting and diarrhea also dose-related. The GI side-effect profile is broadly consistent with other GLP-1 receptor agonists. Because orforglipron is a single-agonist drug, it does not carry the additional pharmacological complexity of glucagon receptor activation.

Phase 3 data across the GLP-1 class has also raised body-composition questions, particularly around lean-mass change during rapid weight loss. Research tracking that signal is collected in our GLP-1 and lean-mass data review.

Neither compound has completed full regulatory safety review; complete tolerability profiles will be defined by totality-of-evidence across the TRIUMPH and ATTAIN Phase 3 programs.

Which One Is Closer to Approval?

As of May 28, 2026, Foundayo has already won the regulatory race. Lilly filed for obesity in early 2026 and FDA approved orforglipron under the brand name Foundayo on April 1, 2026 — the first oral non-peptide GLP-1 receptor agonist approved for chronic weight management, issued under the Commissioner’s National Priority Voucher pilot programme 50 days after filing. The UAE EDE subsequently announced approval in early April 2026. The ATTAIN-MAINTAIN trial (May 12, 2026) added a maintenance-dosing use case — Foundayo plus lower-dose Zepbound held weight after switching from max-tolerated Wegovy with modest regain (~0.9–5 kg by cohort). A separate ATTAIN post-hoc analysis showed comparable weight loss in older adults aged 65 and over. Retatrutide is not yet approved but is available in Dubai as a research-grade compound for in-vitro laboratory use.

Retatrutide has a larger clinical program — the TRIUMPH program includes eight Phase 3 trials spanning obesity, type 2 diabetes, MASH, obstructive sleep apnea, HFpEF, and osteoarthritis. Three Phase 3 trials have reported positive results: the pivotal TRIUMPH-1 obesity trial (May 21, 2026, 28.3% at 80 weeks on 12 mg, 30.3% at 104 weeks in the BMI ≥35 extension), TRIUMPH-4 (Dec 2025), and TRANSCEND-T2D-1 (Mar 2026). Lilly has not filed an NDA on retatrutide as of May 28, 2026. TRIUMPH-2 (T2D) and TRIUMPH-3 (established CVD) readouts are expected later in 2026, and full TRIUMPH-1 data will be presented at the ADA Scientific Sessions in June 2026.

Foundayo (orforglipron) is now marketed for chronic weight management under the ATTAIN programme. A U.S. type 2 diabetes submission via the ACHIEVE programme is on a separate filing path, and global regulatory submissions are ongoing.

Lilly is clearly sequencing the two drugs strategically — Foundayo as the oral option first, retatrutide as the higher-efficacy injectable following behind — filing sequentially rather than in parallel.

Market availability in any jurisdiction will depend on regulatory sequencing and supply. For running status across the wider pipeline, see our obesity drug pipeline timeline 2026 and the TRIUMPH trial tracker.

Will Eli Lilly Market Both Drugs?

Almost certainly yes. Retatrutide and orforglipron serve different clinical needs within the same disease area, and Lilly has every commercial incentive to offer both.

Retatrutide — with its triple-agonist mechanism and the highest weight loss figures reported in any late-stage obesity program — positions as the premium option for patients seeking maximum efficacy. Orforglipron — as an oral GLP-1 pill without fasting restrictions — positions as the accessible option for the large population of patients who prefer pills over injections.

This is the same portfolio logic that drives Lilly’s existing strategy with tirzepatide (dual agonist, injectable, marketed as Mounjaro and Zepbound). Adding a triple-agonist injectable and an oral single-agonist creates a full spectrum: injectable dual agonist, injectable triple agonist, and oral single agonist. Each addresses a distinct segment of the obesity market.

Together the two compounds cover the efficacy-versus-convenience axis — which is why research tracking both programs side by side gives a more complete picture than either alone. Explore how all these compounds rank in our best retatrutide supplier Dubai guide.